ALGAE Fundamental Analysis - FERMENTALG

Fundamental Rating

ALGAE gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 72 industry peers in the Chemicals industry. ALGAE has a bad profitability rating. Also its financial health evaluation is rather negative. ALGAE shows excellent growth, but is valued quite expensive already.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year ALGAE has reported negative net income.

ALGAE had a negative operating cash flow in the past year.

In the past 5 years ALGAE always reported negative net income.

ALGAE had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

The Return On Assets of ALGAE (-24.56%) is worse than 90.54% of its industry peers.

ALGAE's Return On Equity of -38.02% is on the low side compared to the rest of the industry. ALGAE is outperformed by 85.14% of its industry peers.

		Industry Rank	Sector Rank
ROA	-24.56%
ROE	-38.02%
ROIC	N/A

ROA(3y)-23.5%

ROA(5y)-19.63%

ROE(3y)-36.23%

ROE(5y)-31.43%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

ALGAE has a worse Gross Margin (20.94%) than 68.92% of its industry peers.

In the last couple of years the Gross Margin of ALGAE has declined.

The Profit Margin and Operating Margin are not available for ALGAE so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	20.94%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y-14.82%

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

ALGAE does not have a ROIC to compare to the WACC, probably because it is not profitable.

ALGAE has more shares outstanding than it did 1 year ago.

Compared to 5 years ago, ALGAE has more shares outstanding

The debt/assets ratio for ALGAE has been reduced compared to a year ago.

2.2 Solvency

Based on the Altman-Z score of 1.36, we must say that ALGAE is in the distress zone and has some risk of bankruptcy.

ALGAE's Altman-Z score of 1.36 is on the low side compared to the rest of the industry. ALGAE is outperformed by 81.08% of its industry peers.

ALGAE has a Debt/Equity ratio of 0.12. This is a healthy value indicating a solid balance between debt and equity.

ALGAE has a better Debt to Equity ratio (0.12) than 79.73% of its industry peers.

		Industry Rank	Sector Rank
Debt/Equity	0.12
Debt/FCF	N/A
Altman-Z	1.36

ROIC/WACCN/A

WACC6.02%

2.3 Liquidity

ALGAE has a Current Ratio of 1.88. This is a normal value and indicates that ALGAE is financially healthy and should not expect problems in meeting its short term obligations.

ALGAE has a Current ratio (1.88) which is comparable to the rest of the industry.

ALGAE has a Quick Ratio of 1.83. This is a normal value and indicates that ALGAE is financially healthy and should not expect problems in meeting its short term obligations.

With an excellent Quick ratio value of 1.83, ALGAE belongs to the best of the industry, outperforming 82.43% of the companies in the same industry.

		Industry Rank	Sector Rank
Current Ratio	1.88
Quick Ratio	1.83

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

ALGAE shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 55.44%, which is quite impressive.

ALGAE shows a strong growth in Revenue. In the last year, the Revenue has grown by 59.05%.

ALGAE shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 43.52% yearly.

EPS 1Y (TTM)55.44%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%54.36%

Revenue 1Y (TTM)59.05%

Revenue growth 3Y26.74%

Revenue growth 5Y43.52%

Sales Q2Q%20.35%

3.2 Future

Based on estimates for the next years, ALGAE will show a quite strong growth in Earnings Per Share. The EPS will grow by 17.96% on average per year.

The Revenue is expected to grow by 39.99% on average over the next years. This is a very strong growth

EPS Next Y30.77%

EPS Next 2Y30.09%

EPS Next 3Y27.59%

EPS Next 5Y17.96%

Revenue Next Year13.04%

Revenue Next 2Y50.36%

Revenue Next 3Y56.76%

Revenue Next 5Y39.99%

3.3 Evolution

The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

ALGAE reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

Also next year ALGAE is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

A more expensive valuation may be justified as ALGAE's earnings are expected to grow with 27.59% in the coming years.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y30.09%

EPS Next 3Y27.59%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

ALGAE does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

FERMENTALG

EPA:ALGAE (12/5/2025, 7:00:00 PM)

0.448

+0.01 (+2.75%)

Chartmill FA Rating

GICS SectorMaterials

GICS IndustryGroupMaterials

GICS IndustryChemicals

Earnings (Last)10-07 2025-10-07

Earnings (Next)01-12 2026-01-12

Inst Owners25.5%

Inst Owner ChangeN/A

Ins Owners2.02%

Ins Owner ChangeN/A

Market Cap40.25M

Revenue(TTM)12.78M

Net Income(TTM)-11.54M

Analysts84.44

Price Target0.73 (62.95%)

Short Float %N/A

Short RatioN/A

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)N/A

Avg EPS beat(2)N/A

Min EPS beat(2)N/A

Max EPS beat(2)N/A

EPS beat(4)N/A

Avg EPS beat(4)N/A

Min EPS beat(4)N/A

Max EPS beat(4)N/A

EPS beat(8)N/A

Avg EPS beat(8)N/A

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)0%

PT rev (3m)0%

EPS NQ rev (1m)N/A

EPS NQ rev (3m)N/A

EPS NY rev (1m)0%

EPS NY rev (3m)-28.57%

Revenue NQ rev (1m)N/A

Revenue NQ rev (3m)N/A

Revenue NY rev (1m)0%

Revenue NY rev (3m)-20.25%

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	3.15
P/FCF	N/A
P/OCF	N/A
P/B	1.33
P/tB	2.57
EV/EBITDA	N/A

EPS(TTM)-0.12

EYN/A

EPS(NY)-0.04

Fwd EYN/A

FCF(TTM)-0.06

FCFYN/A

OCF(TTM)-0.05

OCFYN/A

SpS0.14

BVpS0.34

TBVpS0.17

PEG (NY)N/A

PEG (5Y)N/A

Graham NumberN/A

Profitability

		Industry Rank	Sector Rank
ROA	-24.56%
ROE	-38.02%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	20.94%
FCFM	N/A

ROA(3y)-23.5%

ROA(5y)-19.63%

ROE(3y)-36.23%

ROE(5y)-31.43%

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexgc growth 3YN/A

ROICexgc growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y-14.82%

GM growth 5YN/A

F-Score6

Asset Turnover0.27

Health

		Industry Rank	Sector Rank
Debt/Equity	0.12
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	18.25%
Cap/Sales	3.92%
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	1.88
Quick Ratio	1.83
Altman-Z	1.36

F-Score6

WACC6.02%

ROIC/WACCN/A

Cap/Depr(3y)32.24%

Cap/Depr(5y)108.18%

Cap/Sales(3y)12.02%

Cap/Sales(5y)34.66%

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)55.44%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%54.36%

EPS Next Y30.77%

EPS Next 2Y30.09%

EPS Next 3Y27.59%

EPS Next 5Y17.96%

Revenue 1Y (TTM)59.05%

Revenue growth 3Y26.74%

Revenue growth 5Y43.52%

Sales Q2Q%20.35%

Revenue Next Year13.04%

Revenue Next 2Y50.36%

Revenue Next 3Y56.76%

Revenue Next 5Y39.99%

EBIT growth 1Y15.81%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next Year41.18%

EBIT Next 3Y33.56%

EBIT Next 5Y22.54%

FCF growth 1Y49.35%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y50.34%

OCF growth 3YN/A

OCF growth 5YN/A

FERMENTALG / ALGAE.PA FAQ

What is the ChartMill fundamental rating of FERMENTALG (ALGAE.PA) stock?

ChartMill assigns a fundamental rating of 3 / 10 to ALGAE.PA.

What is the valuation status of FERMENTALG (ALGAE.PA) stock?

ChartMill assigns a valuation rating of 1 / 10 to FERMENTALG (ALGAE.PA). This can be considered as Overvalued.

Can you provide the profitability details for FERMENTALG?

FERMENTALG (ALGAE.PA) has a profitability rating of 0 / 10.

What is the financial health of FERMENTALG (ALGAE.PA) stock?

The financial health rating of FERMENTALG (ALGAE.PA) is 3 / 10.

FERMENTALG (ALGAE.PA) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens

FERMENTALG / ALGAE.PA FAQ

What is the ChartMill fundamental rating of FERMENTALG (ALGAE.PA) stock?

What is the valuation status of FERMENTALG (ALGAE.PA) stock?

Can you provide the profitability details for FERMENTALG?

What is the financial health of FERMENTALG (ALGAE.PA) stock?